ClinicalTrials.Veeva

Menu

Treatment Outcome Between Mycobacterium Abscessus Infection in Chronic Lung Disease and Acquired Interferon-gamma Autoantibody Syndrome

K

King Chulalongkorn Memorial Hospital

Status

Completed

Conditions

Mycobacterium Abscessus Infection
Nontuberculous Mycobacterial Pulmonary Infection
Adult-Onset Immunodeficiency With Acquired Anti-Interferon-Gamma Autoantibodies

Treatments

Drug: Appropriate treatment

Study type

Observational

Funder types

Other

Identifiers

NCT05354583
46/2565

Details and patient eligibility

About

The treatment outcome of Mycobacterium abscessus infection in acquired interferon-gamma autoantibody syndrome has not been well studied. Investigators will perform a retrospective and prospective cohort study to determine the treatment outcome of Mycobacterium abscessus infection in patients with acquired interferon-gamma autoantibody syndrome compared with the infection in patients with chronic lung disease which is known to be the most common group of infection and have high rates of treatment failure. Investigators hypothesized that Mycobacterium abscessus infection in acquired interferon-gamma autoantibody syndrome has better outcome than infection in chronic lung disease.

Full description

The single center, retrospective and prospective cohort study including the patients, aged 18 years and over, with acquired interferon-gamma autoantibody syndrome or chronic lung disease diagnosed with M. abscessus infection in the tertiary hospital of Thailand from January 2014 to June 2023 will be perform. The enrolled M. abscessus infected patients will be divided into two groups which are acquired interferon-gamma autoantibody syndrome group and chronic lung disease group. The subjects' medical record will be reviewed for demographic data, underlying diseases, clinical signs and symptoms, laboratory and radiological investigation results, diagnosis, treatment that the patients received, clinical events during the treatment. The treatment outcome will be determined as unfavorable or favorable by present or absent of unfavorable events, settled by the investigators, within 1 years after the treatment. The treatment outcome and other secondary outcomes between the two groups will then be compared and analysed with chi-squared test for categorical variables and two-sample t-test for continuous variables.

Enrollment

36 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Aged 18 years or over
  • Diagnosed with Mycobacterium abscessus pulmonary disease in chronic lung disease or Mycobacterium abscessus infection in acquired interferon-gamma autoantibody syndrome
  • Receive appropriate treatment

Exclusion criteria

  • Follow up time less than one year after the start of appropriate treatment
  • Very incomplete medical record that the subject's history cannot be reviewed
  • Appropriate treatment duration less than one year at the study completion

Trial design

36 participants in 2 patient groups

Acquired Interferon-gamma Autoantibody Syndrome
Description:
Patients infected with M. abscessus at any site, who have acquired interferon-gamma autoantibody syndrome defined as one of the following features: 1. The M. abscessus infection site is lymph node. 2. The M. abscessus infection is disseminated (more than 1 organ of infection or blood culture positive for M. abscessus). 3. The M. abscessus infection is accompanied by one of reactive skin diseases which are Sweet's syndrome, pustular psoriasis, erythema nodosum. 4. History of opportunistic infection such as salmonellosis, penicillosis, histoplasmosis, cryptococcosis, melioidosis The patients must not be infected with HIV, in-hospital M. abscessus infection, diagnosed with cancer, or receiving immunosuppressants.
Treatment:
Drug: Appropriate treatment
Chronic Lung Disease
Description:
Patients with one of chronic lung diseases which are COPD, chronic bronchiectasis, history of pulmonary tuberculosis and diagnosed with Pulmonary M. abscessus infection. Pulmonary M. abscessus infection diagnosis must be met all of the following criteria: 1. Symptoms and signs are correlated with the pulmonary M. abscessus infection. 2. One of the radiological evidences: 2.1) nodular infiltration or cavitary lesion on plain chest radiography 2.2) bronchiectasis and multiple small nodules on chest computerized tomography 3. Mycobacterial culture from respiratory tract specimen is positive for M. abscessus
Treatment:
Drug: Appropriate treatment

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems